Center for Global Health Faculty

Academic Degrees

Departmental Address

Contact Information

Email:

seshlem+jhmi.edu

Phone:

410-614-4734

Fax:

410-502-9244

Link:

SciVal Experts Research Profile

Research and Professional Experience

Dr. Eshleman's HIV research program includes basic, translational, and clinical research. Her basic research program is focused on further defining the genetic diversity of HIV strains, and the impact of this diversity on HIV transmission, pathogenesis, and response to treatment. Her translational research program is focused on development and validation of assays for HIV analysis, with a particular emphasis on assays for HIV drug resistance and analysis of non-subtype B strains. She is also coordinates a technology transfer initiative, transferring HIV genotyping technology to international laboratories. Her clinical research program involves participation as a virologist and clinical pathologist in clinical trials for HIV prevention and treatment. She is the PI and Director of the HIV Prevention Trials Network laboratory, and also participates in clinical trials in the IMPAACT network.

Keywords

HIV drug resistance, HIV prevention, HIV mother-to-child transmission, HIV diversity

Honors and Awards

1980 Association of M.I.T. Alumnae Senior Academic Award 1987 Upjohn Achievement Award for Excellence in Biomedical Research 1992 ACLPS Young Investigator Award for Excellence in Research 1992-93 MetPath Fellowship in Laboratory Medicine (MetPath, Inc.) 2000 Faculty Teaching Award (Dept. of Pathology, JHU) 2001 Poster Award for Outstanding Content and Presentation, 5th International Workshop on HIV Drug Resistance and Treatment Strategies. Scottsdale, AZ.

Selected Publications

Eshleman SH, Laeyendecker O, Parkin N, Huang W, Chappey C, Paquet AC, Serwadda D, Reynolds SJ, Kiwanuka N, Quinn TC, Gray R and Wawer M. Antiretroviral drug susceptibility among drug naïve adults with recent HIV infection in Rakai, Uganda. AIDS. 2009, In Press.

Wind-Rotolo, M, Durand C, Cranmer L, Reid A, Martinson N, Doherty M, Jilek BL, Kagaayi J, Kiiza A, Pillay V, Laeyendecker O, Reynolds SJ, Eshleman SH, Lau B, Ray SC, Siliciano JD, Quinn TC, and Siliciano RF. Identification of nevirapine-resistant HIV-1 in the latent reservoir of women following single dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis. 2009, In Press.

Eshleman SH, Hudelson SE, Smith P, Hackett J, Holzmayer V, Swanson P, Devare SG, and Marlowe N. Analysis of pol integrase sequences in diverse HIV-1 strains using a prototype genotyping assay. AIDS Res Hum Retroviruses. 2009, In Press.

Church JD, Omer SB, Guay LA, Huang W, Lidstrom J, Musoke P, Mmiro F, Jackson JB, and Eshleman SH. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-dose (SD) NVP versus SD nevirapine (NVP) plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis. 2008, 198:1075-1082.

Towler WI, Church JD, Eshleman JR, Fowler MG, Guay LA, Jackson JB, and Eshleman SH. Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq). AIDS Research Hum Retroviruses. 2008, 24:1209-1203.

Flys TS, McConnell MS, Matovu F, Church JD, Bagenda D, Khaki L, Bakaki P, Thigpen MC, Eure C, Fowler MG, and Eshleman SH. Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. J Infect Dis, 2008. 198:465-469.

Church JD, Huang W, Mwatha A, Toma J, Stawiski E, Donnell D, Guay LA, Mmiro F, Musoke P, Jackson JB, Parkin N, and Eshleman SH. HIV-1 tropism and survival in vertically infected Ugandan infants. J Infect Dis. 2008, 197:1382-1388.

Collier AC, Tierney C, Downey GF, Eshleman SH, Kashuba A, Klingman K, Vergis EN, Pakes GE, Rooney J, Rinehart A, and Mellors JW. Randomized study of dual vs. single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV infection. HIV Clinical Trials. 2008, 9:91-102.

Church JD, Towler WI, Hoover DR, Hudelson SE, Kumwenda N, Taha TE, Eshleman JR, and Eshleman SH. Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variants. AIDS Res Human Retroviruses. 2008, 24:595-605.

Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman SH, Spreen W, Nguyen B-Y, Koval CE, Eron JJ, Hammer S, and Squires K. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clinical Trials. 2008, 9:11-25.

Eshleman SH, Hudelson SE, Bruce R, Lee T, Owens MR, Hackett J, Swanson P, Devare SG, and Marlowe N. Analysis of HIV type 1 gp41 sequences in diverse HIV type 1 strains. AIDS Res Human Retroviruses. 2007, 23:1593-1598.

Flys TS, Mwatha A, Guay LA, Nakabiito C, Donnell D, Musoke P, Mmiro F, Jackson JB, and Eshleman SH. Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine. AIDS. 2007, 21:2077-2082.

Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, Paxinos EE, Whitcomb JM, Young AM, Donnell D, Mmiro F, Musoke P, Guay LA, Jackson JB, Parkin N, and Petropoulos CJ. Co-receptor tropism in subtype D HIV-1: High prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol. 2007, 81:7885-7893.

Church JD, Hudelson SE, Guay LA, Chen S, Hoover DR, Parkin N, Fiscus SA, Mmiro F, Musoke P, Kumwenda N, Jackson JB, Taha TE, and Eshleman SH. HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naïve African women with subtypes A, C, and D. AIDS Res Human Retroviruses. 2007, 23:764-768.

Eshleman SH, Husnik M, Hudelson S, Donnell D, Huang Y, Huang W, Hart S, Jackson B, Coates T, Chesney M, and Koblin B. Analysis of drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS. 2007, 21:1165-1174.

Flys TS, Donnell D, Mwatha A, Nakabiito, C, Musoke P, Mmiro F, Jackson JB, Guay LA, and Eshleman SH. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis. 2007, 195:711-715.

Church JD, Jones D, Flys T, Hoover D, Marlowe N, Chen S, Shi C, Eshleman JR, Guay LA, Jackson JB, Kumwenda N, Taha TE, Eshleman SH. Sensitivity of the ViroSeq HIV-1 Genotyping System for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagnostics. 2006, 8:430-432.